Weed, Inc. (BUDZ): Depreciation & Amortization
$22.5K
Year ended 2025-12-31
$22.3K
Trailing 12 months to 2026-06-30
-41.3%
3-year compound annual growth
-31.2%
5-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $22.5K | -0.4% | 2026-04-08, From 2025-01-01 |
| 2024-12-31 | $22.6K | -56.9% | 2026-04-08, From 2024-01-01 |
| 2023-12-31 | $52.4K | -53.0% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $111.4K | -14.1% | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | $129.8K | -11.0% | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $145.8K | -8.5% | 2022-03-31, From 2020-01-01 |
| 2019-12-31 | $159.4K | -11.7% | 2021-03-31, From 2019-01-01 |
| 2018-12-31 | $180.6K | +304.5% | 2020-03-30, From 2018-01-01 |
| 2017-12-31 | $44.7K | n/a | 2019-04-16, From 2017-01-01 |
| No annual figure between 2011-12-31 and 2017-12-31. | |||
| 2011-12-31 | $1.8K | 0.0% | 2012-04-16, From 2011-01-01 |
| 2010-12-31 | $1.8K | n/a | 2012-04-16, From 2010-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Weed, Inc. (BUDZ) | 2025-12-31 | $22.5K | -0.4% |
| NRC Health (NRC) | 2025-12-31 | $7.62M | +26.6% |
| Incyte Corp (INCY) | 2025-12-31 | $93.29M | +4.5% |
| Icon PLC (ICLR) | 2025-12-31 | $383.00M | -21.6% |
| Charles River Laboratories International, Inc. (CRL) | 2025-12-27 | $403.31M | +11.5% |
| MaxCyte, Inc. (MXCT) | 2025-12-31 | $4.34M | +0.6% |
| Iqvia Holdings Inc. (IQV) | 2025-12-31 | $1.14B | +2.7% |
| iSpecimen Inc. (ISPC) | 2025-12-31 | $1.73M | -24.6% |
| Absci Corp (ABSI) | 2025-12-31 | $11.74M | -12.3% |
Compare BUDZ, NRC, INCY, ICLR side by side · Screen every company in Services-Commercial Physical & Biological Research ↗